Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Belumosudil Tablets and Capsules
NCT02557139Phase 1Completed
- Sponsor
- Kadmon
- Start
- Sep 2015
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of belumosudil in chronic graft-versus-host disease (cGVHD) (3 arms), sponsored by Kadmon. Primary endpoints: Maximum Plasma Concentration and Area Under the Concentration-Time Curve. Started Sep 2015; status: completed.
02
Drugs
belumosudil
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT02557139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02557139.